Exact tests using two correlated binomial variables in contemporary cancer clinical trials

Related Experiment Video

Updated: Jun 17, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Jihnhee Yu1, James L Kepner, Renuka Iyer

  • 1Department of Biostatistics, University at Buffalo, State University of New York, Buffalo, NY, USA. jinheeyu@buffalo.edu

Biometrical Journal. Biometrische Zeitschrift
|December 17, 2009
PubMed

Insights

New cancer therapies require updated clinical trial methods. This study introduces an exact statistical test for cytostatic cancer treatments, improving efficiency and potentially reducing sample size requirements.

Area of Science:

  • Oncology
  • Biostatistics
  • Genetics

Background:

  • Advances in cancer genetics and molecular biology are driving the development of novel targeted therapies.
  • Current clinical trial designs may be inadequate for evaluating newer cancer treatments that improve survival without significant tumor shrinkage.
  • There is a need for improved statistical methods to accurately assess the efficacy of cytostatic cancer therapies.

Purpose of the Study:

  • To propose an exact statistical method for testing cytostatic cancer treatments.
  • To simultaneously assess two primary outcomes using correlated bivariate binomial random variables.
  • To provide a more suitable analysis method for emerging cancer therapies.

Main Methods:

  • Development of an exact statistical test for cytostatic cancer treatment efficacy.
  • Utilizing correlated bivariate binomial random variables for simultaneous assessment of two outcomes.
  • Providing sample size calculations for specific study designs.

Main Results:

  • The proposed method is easy to implement in clinical trial analysis.
  • The method does not increase sample size compared to univariate exact tests.
  • In many cases, the proposed method reduces the required sample size.

Conclusions:

  • The developed exact method offers a more efficient approach to testing cytostatic cancer treatments.
  • This statistical advancement can better detect therapeutic effects of novel cancer therapies.
  • The method supports improved clinical trial design and analysis for emerging oncology treatments.

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
The Mantel-Cox Log-Rank Test01:19

The Mantel-Cox Log-Rank Test

The Mantel-Cox log-rank test is a widely used statistical method for comparing the survival distributions of two groups. It tests whether a statistically significant difference exists in survival times between the groups without assuming a specific distribution for the survival data, making it a non-parametric test. This flexibility makes the log-rank test particularly valuable in medical research and other fields where the timing of an event, such as death or disease recurrence, is of interest.
McNemar's Test01:23

McNemar's Test

McNemar's Test is a nonparametric statistical test used to determine if there is a significant difference in proportions between two related groups when the outcome is binary (e.g., yes/no, success/failure). It is beneficial when we have paired data, such as pre-test/post-test designs, where the same subjects are measured under two different conditions. The test is named after the statistician Quinn McNemar, who introduced it in 1947. It is commonly used in situations where subjects are...